A5009612654- Venous Thromboembolism Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Atrial Fibrillation Management and Outcomes
- Blood Pressure and Hypertension Studies
- Diagnosis and Treatment of Venous Diseases
- Lipoproteins and Cardiovascular Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Folate and B Vitamins Research
- COVID-19 Clinical Research Studies
- Cardiac Arrhythmias and Treatments
- Long-Term Effects of COVID-19
- Vascular anomalies and interventions
- Cerebral Venous Sinus Thrombosis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Opioid Use Disorder Treatment
- HIV-related health complications and treatments
- Pain Management and Opioid Use
- Reproductive Health and Contraception
- Acute Myocardial Infarction Research
- Cytomegalovirus and herpesvirus research
- Peripheral Artery Disease Management
- Cardiovascular Issues in Pregnancy
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Disease and Adiposity
- Hemophilia Treatment and Research
Federatie Medisch Specialisten
2021-2025
Leiden University Medical Center
2015-2024
Shiraz University of Medical Sciences
2021
Leiden University
2010-2020
Loyola University Medical Center
2018
Sanquin
2017
University Medical Center Groningen
2006-2015
University of Groningen
2012-2015
University of Novi Sad
2015
Amsterdam UMC Location University of Amsterdam
2010-2015
Background: Patients with atrial fibrillation generally require anticoagulant therapy and, at times, additional platelet aggregation inhibitors. Data are scarce on bleeding rates in high-risk groups receiving combination therapy, such as the elderly or patients a high CHA 2 DS -VASc score. Methods: We conducted nationwide cohort study of Danish ≥50 years age. Treatments were ascertained from prescription database. These included no treatment, and treatment vitamin K antagonists, direct oral...
Background— The risk of recurrent venous thrombosis is 2-fold higher in men than women. In contrast, no such sex difference the first has been reported. We hypothesized that, for a event, between sexes masked by female exposure to reproductive factors (oral contraception, pregnancy/puerperium, and postmenopausal hormone therapy). Methods Results— From Multiple Environmental Genetic Assessment Risk Factors Venous Thrombosis (MEGA) study, population-based case-control study on thrombosis, 2915...
Background— Homozygous or double heterozygous factor V Leiden and/or prothrombin G20210A is a rare inherited thrombophilic trait. Whether individuals with this genetic background have an increased risk of recurrent venous thrombosis uncertain. Methods and Results— A case-control design within large cohort families thrombophilia was chosen to calculate the in homozygosity heterozygosity G20210A. Cases were thrombosis, controls those only 1 thrombosis. The consisted 788 thrombosis; 357 had...
<h3>Importance</h3> An increase in opioid prescription has been observed the Netherlands. It is vital to understand this and identify risk factors for ensure that health interventions remain appropriately targeted. <h3>Objectives</h3> To determine prevalence of prescriptions adverse events associated with opioids, Dutch population. <h3>Design, Setting, Participants</h3> This cohort study used national statistics from Netherlands January 1, 2013, December 31, 2017, including full population...
ObjectivesTo test whether Bacillus Calmette-Guérin (BCG) vaccination would reduce the incidence of COVID-19 and other respiratory tract infections (RTIs) in older adults with one or more comorbidities.MethodsCommunity-dwelling aged 60 years underlying comorbidities no contraindications to BCG were randomized 1:1 placebo followed for 6 months. The primary endpoint was a self-reported, test-confirmed incidence. Secondary endpoints included hospital admissions clinically relevant RTIs (i.e....
Hereditary deficiencies of protein S, C and antithrombin are known risk factors for first venous thromboembolism. We assessed the absolute recurrence, contribution concomitant thrombophilic defects in a large cohort families with these deficiencies. Annual incidence recurrence was estimated 130 deficient patients, separate estimates those each C, deficiency, eight non-deficient patients prior All were also tested factor V Leiden, prothrombin G20210A, high levels VIII, IX XI,...
Advanced glycation end products play a pivotal role in atherosclerosis. Recently, we showed that tissue advanced deposition, noninvasively assessed by skin autofluorescence (SAF), is increased patients with peripheral artery disease. The aim of the present study was to establish whether SAF associated all-cause mortality and fatal or nonfatal major adverse cardiovascular events (MACE) disease.We performed single-center prospective cohort 252 disease (mean age, 66±11 years), recruited from...
Venous thrombosis is a major contributor to the global disease burden. In this review we aim answer two important questions: (1) are making progress in reducing burden and (2) how can further improve? To these questions, first evaluated burden, that is, incidence of venous over past decade(s) discuss its most determinants. We found remained relatively unchanged, despite an increase risk factor prevalence rise identification subsegmental pulmonary emboli due enhanced image quality...
Hypertension during pregnancy and preeclampsia are associated with increased arterial thrombotic risk in later life. Whether these complications of venous thromboembolism (VTE) on the short term after long term, that is, outside pregnancy, is largely unknown. We conducted a nationwide cohort study women at least 1 their first VTE by linking Dutch perinatal registry (Perined) to anticoagulation clinics. used Cox proportional hazard models estimate ratios (HRs) corresponding 95% CI for...
<h3>Importance</h3> The size of the risk recurrent venous thromboembolism (VTE) after surgery in patients with a history VTE is not well known. <h3>Objectives</h3> To estimate and to identify factors associated undergoing who have VTE. <h3>Design, Setting, Participants</h3> This population-based, follow-up cohort study includes participated Multiple Environment Genetic Assessment (MEGA) study. Original data were collected from March 1999 April 2010. Data analysis began June ended...